Amitriptyline for Gastrointestinal Pain
Start amitriptyline at 10 mg once nightly and titrate by 10 mg weekly or biweekly to a maximum of 30-50 mg once nightly, based on symptom response and tolerability. This dosing strategy is effective for both functional dyspepsia and IBS as second-line treatment when first-line therapies (PPIs, H. pylori eradication, antispasmodics) have failed 1, 2.
Starting Dose and Titration
- Initial dose: 10 mg at bedtime 1, 2
- Titration schedule: Increase by 10 mg per week OR per fortnight depending on response and side effects 2
- Target dose: 30-50 mg once nightly 1, 2
- Do not exceed 50 mg for functional GI disorders (this is substantially lower than the 75-300 mg used for depression) 3
The evidence strongly supports this low-dose approach. The ATLANTIS trial—the largest TCA study in IBS ever conducted with 463 patients—demonstrated significant superiority over placebo using this exact titration protocol, with a mean IBS-SSS score improvement of -27.0 points at 6 months 4, 5.
Evidence for Efficacy
For IBS: Tricyclic antidepressants rank first for pain relief in network meta-analyses, outperforming antispasmodics and PPIs 2. The ATLANTIS trial showed amitriptyline was superior to placebo for:
- Global IBS symptoms (IBS-SSS score difference -27.0, p=0.008) 4, 5
- Subjective relief (OR 1.78, p=0.005) 4
- Individual symptom components across all IBS subtypes 6
For functional dyspepsia: TCAs are recommended as second-line treatment with strong evidence (moderate quality) 1. They ranked second in network meta-analyses for FD treatment, ahead of PPIs, even though trials recruited patients who had already failed PPI therapy 2.
Patient Selection and Predictors of Response
Amitriptyline appears particularly effective in:
- Patients ≥50 years old (mean difference -46.5 on IBS-SSS, p=0.001) 6
- IBS with diarrhea subtype (OR 10.55 for diarrhea improvement) 7
- Higher somatic symptom burden (higher PHQ-12 scores) 6
- Male patients showed stronger treatment effects 6
However, amitriptyline demonstrates efficacy across all IBS subtypes with similar side effect profiles, so subtype should not preclude its use 6.
Safety Considerations and Common Pitfalls
Expected side effects (counsel patients beforehand) 2:
- Sedation (often beneficial for sleep)
- Dry mouth and dry eyes
- Constipation (particularly relevant in IBS-C)
Critical counseling points to improve adherence 8:
- Explain this is NOT being prescribed as an antidepressant—this is the most common patient concern that leads to non-adherence 8
- Emphasize the dose is 3-10 times lower than antidepressant dosing
- Highlight the analgesic and gut-brain neuromodulator effects
- Mention potential sleep benefits as an additional advantage
- Empower patients with self-titration guidance
Discontinuation rates: In ATLANTIS, 13% discontinued amitriptyline due to adverse events versus 9% for placebo—most adverse events were mild 4, 5. This is acceptable given the significant symptom improvement.
Contraindications to screen for:
- Recent myocardial infarction
- Arrhythmias (particularly heart block)
- Concurrent MAO inhibitor use
- Narrow-angle glaucoma
- Urinary retention
- Suicidal ideation 4
Timeline for Response
- Sedative effects may appear immediately (beneficial for sleep) 3
- Therapeutic effect on GI symptoms typically requires 4-8 weeks 9, 10
- Continue for at least 3 months before considering treatment failure 3
When to Use as Second-Line
Use amitriptyline when:
- First-line therapies have failed (dietary modification, antispasmodics, PPIs for FD, fiber/laxatives/antidiarrheals for IBS) 1, 2
- Symptoms remain moderate-to-severe (IBS-SSS ≥75) 4, 5
- Patient has been counseled about the rationale and side effects 1
Can be initiated in primary care—specialist referral is not required, though the British Society of Gastroenterology recommends access to specialist clinics for refractory cases 1.
Comparison to Other Neuromodulators
While SSRIs showed no benefit in meta-analyses 2, and SNRIs like duloxetine have limited evidence in functional GI disorders (despite efficacy in other chronic pain conditions) 2, amitriptyline has the strongest evidence base among neuromodulators for both IBS and functional dyspepsia. Secondary amine TCAs (nortriptyline, desipramine) may have fewer anticholinergic side effects than amitriptyline but have less robust evidence 2.